AI Article Synopsis
- Double-hit lymphoma (DHL) is a high-risk type of large B-cell lymphoma characterized by specific genetic rearrangements and is diagnosed using histology, immunophenotyping, and FISH techniques.
- * DHL can vary in appearance and is typically of the germinal center B-cell type, with prognosis affected by factors like elevated LDH levels and disease stage.
- * Advances in treatment, including intensive chemotherapy and innovative therapies like CAR-T cells, show promise for improving outcomes, especially in cases that are resistant to standard therapies.
Article Abstract
Double-hit lymphoma (DHL) is a high-risk subtype of large B-cell lymphoma, defined by concurrent rearrangements and . The diagnosis is confirmed through histologic and immunophenotypic examination and fluorescence hybridization (FISH) to demonstrate the rearrangements. DHL morphology ranges from DLBCL to high-grade B-cell lymphoma which can resemble Burkitt lymphoma and is almost always germinal center B-cell like (GCB). Prognosis is influenced by elevated lactate dehydrogenase (LDH), advanced stage, and extranodal involvement, among other factors. Treatment outcomes vary, but intensive chemotherapy regimens such as dose-adjusted EPOCH-R have shown the most promising results, though low-risk cases do occur and may do well with less intensive treatments. Recent therapeutic advances such as CAR-T cells and bispecific antibodies offer promise for patients with relapsed/refractory disease. This review synthesizes data from recent literature to provide a comprehensive analysis of the molecular underpinnings, diagnostic criteria, prognostic factors, and therapeutic strategies for DHL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2024.2412295 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymphomas With Primary Gastrointestinal Presentation: A Retrospective Study Covering a Five-Year Period at a Quaternary Care Center in Southern India.
Cureus
December 2024
Department of Histopathology and Cytology, Apollo Cancer Center, Chennai, IND.
Background and objective Lymphomas can involve the gastrointestinal (GI) tract as a primary disease or as a secondary spread of systemic disease. The GI tract is a key site for extranodal lymphomas, with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring in this region. This study aimed to analyze the demography, anatomic distribution, histological subtypes, and immunomorphological characteristics of all lymphomas with a primary GI presentation at a quaternary care hospital in southern India.
View Article and Find Full Text PDFPrognostic model based on M2 macrophage-related signatures for predicting outcomes, enhancing risk stratification, and providing therapeutic insights in diffuse large B-cell lymphoma.
Heliyon
December 2024
Department of Hematology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China.
Purpose: The tumor microenvironment (TME) in lymphoma is influenced by M2 macrophages. This research proposes an novel predictive model that leverages M2 macrophage-associated genes to categorize risk, forecast outcomes, and evaluate the immune profile in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) undergoing R-CHOP therapy.
Methods: Gene expression data and clinical information from DLBCL patients were retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.
Follicular Helper T-cell Lymphoma With Hodgkin/Reed-Sternberg-Like Cells Versus Classic Hodgkin Lymphoma: A Comparative Study.
Am J Surg Pathol
January 2025
Department of Pathology, University Hospital Henri Mondor, AP-HP, Créteil, France.
Lymphomas of T-follicular helper origin (T-follicular helper-cell lymphoma [TFHL]) are often accompanied by an expansion of B-immunoblasts, occasionally with Hodgkin/Reed-Sternberg-like (HRS-like) cells, making the differential diagnosis with classic Hodgkin lymphoma (CHL) difficult. We compared the morphologic, immunophenotypic, and molecular features of 15 TFHL and 12 CHL samples and discussed 4 challenging cases of uncertain diagnosis. Compared with CHL, TFHL disclosed more frequent sparing of subcortical sinuses, high-endothelium venule proliferation, dendritic cell meshwork expansion, T-cell atypia, and aberrant T-cell immunophenotype.
View Article and Find Full Text PDFLimited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell Lymphoma Patients in Complete Remission Following First-Line Treatment.
Am J Hematol
January 2025
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Despite advances in treatment, approximately 15% of patients with diffuse large B-cell lymphoma (DLBCL) who achieve complete remission (CR) after first-line therapy will experience a relapse. However, there is no consensus on the optimal follow-up strategies for detecting relapse after achieving CR. This population-based study, based on the Danish Lymphoma Registry (LYFO), identified a total of 1634 patients diagnosed with DLBCL between 2010 and 2017, including 105 patients who achieved CR following first-line R-CHOP-like therapy and subsequently relapsed.
View Article and Find Full Text PDFComplex Karyotype in a Pediatric Patient with Double-Hit BCL6 High-Grade B-Cell Lymphoma.
Pediatr Blood Cancer
January 2025
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!